2009
DOI: 10.1182/blood-2008-10-186601
|View full text |Cite
|
Sign up to set email alerts
|

IL-7 administration drives T cell–cycle entry and expansion in HIV-1 infection

Abstract: Interleukin 7 (IL-7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes. The safety and activity of recombinant human IL-7 (rhIL-7) administration were therefore examined in HIV-infected persons. In this prospective randomized placebocontrolled study, a single subcutaneous dose of rhIL-7 was well tolerated with biologic activity demonstrable at 3 g/kg and a maximum tolerated dose of 30 g/kg.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

15
275
4
7

Year Published

2009
2009
2023
2023

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 294 publications
(301 citation statements)
references
References 37 publications
15
275
4
7
Order By: Relevance
“…35 The present results extend evidence reported by us in the setting of MA transplantation, 13 but the time when IL-7 levels appeared to be predictive was later after RIC (day þ 30) than after MA regimen (day þ 15), in agreement with the later development of acute GVHD with RIC allo-SCT. 1,2 The present study and other reports 13,17 showing that higher IL-7 levels predate the onset of acute GVHD, and thus, raises a possible limitation of the therapeutic administration of recombinant human IL-7 aiming at improving T-cell reconstitution following lymphopenia 25,32,36 in the case of allo-SCT recipients.…”
Section: Discussionmentioning
confidence: 89%
See 1 more Smart Citation
“…35 The present results extend evidence reported by us in the setting of MA transplantation, 13 but the time when IL-7 levels appeared to be predictive was later after RIC (day þ 30) than after MA regimen (day þ 15), in agreement with the later development of acute GVHD with RIC allo-SCT. 1,2 The present study and other reports 13,17 showing that higher IL-7 levels predate the onset of acute GVHD, and thus, raises a possible limitation of the therapeutic administration of recombinant human IL-7 aiming at improving T-cell reconstitution following lymphopenia 25,32,36 in the case of allo-SCT recipients.…”
Section: Discussionmentioning
confidence: 89%
“…31 High systemic IL-7 levels may, therefore, potentiate alloresponses of the donor T cells against disparate histocompatibility Ags, even more so that IL-7 does not induce a disproportionate expansion of regulatory T cells in humans. 23,32 Experimentally, T cells that have undergone HPE develop augmented alloimmune responses, 33 and clinically, lymphodepletion followed by donor lymphocyte infusion induces more acute GVHD than in T-cell replete recipients. 34 We are aware of a single report on the association of serum IL-7 levels with acute GVHD after RIC transplantation, 17 but in this study all 31 patients were given up to three cycles of intense induction chemotherapy before RIC, and ensuing peak levels of IL-7 were much higher than those commonly observed after MA conditioning.…”
Section: Discussionmentioning
confidence: 99%
“…10). Moreover, in recent clinical trials, the administration of recombinant IL-7 led to a transient entry of T lymphocytes into the cycle, albeit with a rapid return to quiescence (11)(12)(13)(14)(15).…”
mentioning
confidence: 99%
“…Зниження вірусного навантаження завдяки АРТ було пов'язано з нормалізацією реакції двоспрямованої взаємодії між В-клітинами та CD4 + Т-лімфоцитами. Враховуючи, що нормалізація функцій субпопуляцій В-клітин також від-бувається при застосуванні АРТ, можливо припустити, що порушення двоспрямованої взаємодії між В-клітинами та CD4 + Т-лімфоцитами у ВІЛ-інфікованих осіб з високим вірусним навантаженням, по меншій мірі частково, є результатом переважання субпопуляцій В-клітин, що не відповідають на антигенну стимуляцію [26,[38][39][40][41][42][43].…”
Section: (87)2017 інфекційні хворобиunclassified